Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer

Patients with residual disease usually have a poor prognosis after neoadjuvant chemotherapy for breast cancer. The aim of this study was to explore therapeutic targets and potential additional adjuvant treatments for patients with residual disease after standard neoadjuvant chemotherapy. We retrieve...

Full description

Saved in:
Bibliographic Details
Published in:Clinical breast cancer 2020-04, Vol.20 (2), p.117-124.e4
Main Authors: Takahashi, Yuko, Iwamoto, Takayuki, Suzuki, Yoko, Kajiwara, Yukiko, Hatono, Minami, Tsukioki, Takahiro, Kawada, Kengo, Kochi, Mariko, Ikeda, Hirokuni, Shien, Tadahiko, Taira, Naruto, Matsuoka, Junji, Doihara, Hiroyoshi, Toyooka, Shinichi
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - pharmacology
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biomarkers, Tumor - analysis
Biomarkers, Tumor - antagonists & inhibitors
Biomarkers, Tumor - genetics
Breast - pathology
Breast Neoplasms - genetics
Breast Neoplasms - pathology
Breast Neoplasms - therapy
Chemotherapy, Adjuvant
Datasets as Topic
Female
Gene expression
Gene Expression Profiling
Hormone receptor positive
Humans
Middle Aged
Molecular Targeted Therapy - methods
Neoadjuvant Therapy
Neoplasm, Residual
Oligonucleotide Array Sequence Analysis
Receptor, ErbB-2 - analysis
Residual tumor burden
Retrospective Studies
Targeted therapy
Triple negative
Tumor Burden
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with residual disease usually have a poor prognosis after neoadjuvant chemotherapy for breast cancer. The aim of this study was to explore therapeutic targets and potential additional adjuvant treatments for patients with residual disease after standard neoadjuvant chemotherapy. We retrieved publicly available complementary DNA microarray data from 399 human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer samples from patients who underwent standard neoadjuvant chemotherapy. We analyzed the messenger RNA (mRNA) expression levels of key breast cancer markers and therapeutic target genes according to residual cancer burden (RCB) classification: RCB-0/I, RCB-II, and RCB-III. Among hormone receptor–positive samples, there were more luminal A tumors by PAM50 (Prediction Analysis of Microarray 50 [Prosigna], aka Prosigna Breast Cancer Prognostic Gene Signature Assay) in RCB-III than in RCB-0/I and RCB-II (P 
ISSN:1526-8209
1938-0666
DOI:10.1016/j.clbc.2019.07.001